These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3218975)

  • 21. Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.
    Roger P; Monneret C; Fournier JP; Choay P; Gagnet R; Gosse C; Letourneux Y; Atassi G; Gouyette A
    J Med Chem; 1989 Jan; 32(1):16-23. PubMed ID: 2909727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3-(Tetraacetyl glucopyranos-2-yl)-1-(2-chloroethyl)-1-nitrosourea, an antitumor agent with modified bone marrow toxicity.
    Schein PS; McMenamin MG; Anderson T
    Cancer Res; 1973 Sep; 33(9):2005-9. PubMed ID: 4353476
    [No Abstract]   [Full Text] [Related]  

  • 24. Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems.
    Johnston TP; Montgomery JA
    Cancer Treat Rep; 1986 Jan; 70(1):13-30. PubMed ID: 2935250
    [No Abstract]   [Full Text] [Related]  

  • 25. [Dependence of the antitumor activity of nitroso alkyl urea derivatives on their chemical structure].
    Sharashidze LK; Turkiia NG; Lagidze DR; Adamiia IK; Asatiani VV
    Eksp Onkol; 1989; 11(2):62-5. PubMed ID: 2737133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticancer nitrosoureas: investigations on antineoplastic, toxic and neoplastic activities.
    Eisenbrand G
    IARC Sci Publ; 1984; (57):695-708. PubMed ID: 6533062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
    Mulcahy RT; Siemann DW
    Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antitumor effect of compounds synthesized in the Division of Synthetic Chemistry (V) (author's transl)].
    Miyahara M; Kamiya S; Nakadate M; Sueyoshi S; Tanno M; Miyahara M
    Eisei Shikenjo Hokoku; 1981; 99():111-3. PubMed ID: 7332796
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antitumor activity of several new pentopyranosyl-chloroethylnitrosoureas].
    Grouiller A; Navarro ML; Nonga B; Molière P; Santini R; Voulot C; Pacheco H
    C R Seances Soc Biol Fil; 1987; 181(2):128-36. PubMed ID: 2957032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 32. [Experimental studies on oral administration of nitrosourea anti-tumor agent, MCNU].
    Sekido S; Ninomiya K; Araki T; Ueno M; Kinbara M
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1492-500. PubMed ID: 6234861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative effect of administration schedules on the antitumor activities of 3 water-soluble nitrosoureas, ACNU, GANU and MCNU against L1210 leukemia].
    Kato T; Ota K
    Gan To Kagaku Ryoho; 1983 May; 10(5):1354-62. PubMed ID: 6223585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spin labeled amino acid nitrosourea derivatives--synthesis and antitumour activity.
    Zheleva A; Raikov Z; Ilarionova M; Todorov D
    Pharmazie; 1995 Jan; 50(1):25-6. PubMed ID: 7886121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Historical development and future promise of the nitrosoureas as anticancer agents.
    Schabel FM
    Cancer Chemother Rep 3; 1973 May; 4(3):3-6. PubMed ID: 4584035
    [No Abstract]   [Full Text] [Related]  

  • 36. Current status of new agents.
    Carter SK
    Cancer Chemother Rep 3; 1972 May; 3(1):33-47. PubMed ID: 4116662
    [No Abstract]   [Full Text] [Related]  

  • 37. Electronic volume analysis of L1210 chemotherapy.
    Zucker RM; Helfman D
    Cancer Res; 1976 Dec; 36(12):4434-8. PubMed ID: 1000492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
    Carter SK; Schabel FM; Broder LE; Johnston TP
    Adv Cancer Res; 1972; 16():273-332. PubMed ID: 4563045
    [No Abstract]   [Full Text] [Related]  

  • 39. Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas.
    Wheeler GP; Bowdon BJ; Grimsley JA; Lloyd HH
    Cancer Res; 1974 Jan; 34(1):194-200. PubMed ID: 4809457
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Frei E; Schabel FM; Goldin A
    Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.